CClinicalTrials.gg
CompletedNCT04405609PUAAUpdated Jun 4, 2020

Usability Study of "ArmAssist 2.0." Robot: Homecare Arm Rehabilitation in Stroke Patients

An interventional study of ArmAssist in Stroke, Rehabilitation and Upper Limb Rehabilitation, sponsored by Maimónides Biomedical Research Institute of Córdoba. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2019, registered May 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to validate the usability of ArmAssist medical device, a robotic system for the rehabilitation of upper limbs in stroke patients (based on serious games). This study evaluate the usability of the system in a home environment, taking into account the ease-to-use, consistency and others; and will pretend demonstrate the feasibility of including or no, robotic therapy in home like complement of daily rehabilitation program. Finally this study investigate the acceptance from patients and therapists.

02

Conditions studied

  • Stroke
  • Rehabilitation
  • Upper Limb Rehabilitation
  • Telerehabilitation
  • Robot-assisted Therapy

Browse trials for

Keywords

  • Stroke
  • Cerebrovascular Disorders
  • Robotic
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 9 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects over 18,
  • Upper limb hemiparesis after stroke,
  • Unilateral paresis and cognitive ability to understand,
  • Accept and actively participate in the usability study.

Exclusion criteria

Exclusion Criteria:

  • Bilateral motor deficit,
  • Severe spasticity,
  • Psychiatric illness,
  • and/or cognitive impairment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    ArmAssist group

    The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage). Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months. The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians.

    Device: ArmAssist

Interventions

  • DeviceArmAssist

    The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation. The usability study is carried out in two phases: 1. First phase: 5 weeks. 2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support.

06

What researchers measure

Primary outcomes

  1. Quebec User Evaluation of Satisfaction with assistive Technology: QUEST scale

    The purpose of this scale is to evaluate how satisfied the patient are with the assistive device and the related services they experienced. It consists of twelve questions, eight related to the device and four related to services of 12 satisfaction items with answers from 1 'Not satisfied at all' to 5 'Very satisfied'

    Time frame: Through study completion, an average of 3 weeks

  2. System Usability Scale: SUS

    This scale provides a quick, reliable tool for measuring the usability. It consists of 10 item questionnaire and answers from 1 'strongly agree' to 5 'strongly disagree'. Scores are ranging to 0-100 %, where a high score means better usability with a higher score meaning better usability

    Time frame: Through study completion, an average of 3 weeks

  3. Intrinsic Motivation Inventory: IMI

    This scale is a multidimensional scale intended to assess participants subjective experience with the device (interest/enjoyment, perceived competence, effort, value/usefulness, felt pressure and tension, and perceived choice while performing a given activity). Consist of 20 item questionnaire with answers from 1 'strongly agree' to 7 'strongly disagree'.

    Time frame: Through study completion, an average of 3 weeks

  4. Usability questionnaire specifically designed for the use of ArmAssist 2.0

    It consists of a 19 item questionnaire with seven response options (Likert sacle) for respondents; from Strongly agree to Strongly disagree. To evaluate the satisfaction of patients and therapist with the system and the therapy.

    Time frame: Through study completion, an average of 3 weeks

  5. Structured interviews: Willingness-to-pay questionnaire

    This interview consists in two short questions to ask to participants about the willingness-to-pay for ArmAssist 2.0. system as therapy.

    Time frame: Through study completion, an average of 3 weeks

Secondary outcomes

  1. Fugl-Meyer Assessment (FMA) scale

    It is an index to assess the sensorimotor impairment in individuals who have had stroke. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. The maximun score is 66 points

    Time frame: Baseline, 3 weeks

  2. Modified Asworth Scale (MAS)

    This scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. It is single-item measures ranging from 0 to 4, where 0 indicates no increase in muscle tone and 4 indicates that the affected part is rigid in flexion or extension.

    Time frame: Baseline, 3 weeks

07

Study locations

1 site
  • Hospital Universitario Reina Sofía de Córdoba
    Córdoba, 14004, Spain
08

References and documents

Publications

  • Guillen-Climent S, Garzo A, Munoz-Alcaraz MN, Casado-Adam P, Arcas-Ruiz-Ruano J, Mejias-Ruiz M, Mayordomo-Riera FJ. A usability study in patients with stroke using MERLIN, a robotic system based on serious games for upper limb rehabilitation in the home setting. J Neuroeng Rehabil. 2021 Feb 23;18(1):41. doi: 10.1186/s12984-021-00837-z. PubMed 33622344 ↗

Individual participant data

Plan to share: Yes — All the collected information will be available for other researchers upon request.

Supporting information: Study protocol, Icf, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04405609
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
TECNALIA Research & Innovation, GMV Innovating Solutions
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Oct 28, 2019
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Last update
Jun 4, 2020

Study contacts

Fernando Jesus Mayordomo Riera, MD
principal investigator · Hospital Universitario Reina Sofia de Córdoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion